A Phase 2, Prospective, Multicenter, Single-Arm Trial of …
2023年6月5日 · The present phase 2, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the efficacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better objective response rate (ORR) than sorafenib (jRCTs031180074).
ASCO GI速递 | TACTICS研究最终OS结果公布，TACE联合索拉非 …
2021年1月20日 · 在本届ASCO-GI上，由日本学者Masatoshi Kudo教授开展TACTICS研究公布了最终OS结果，即对于不可切除的HCC患者，TACE+索拉非尼治疗可实现长达36.2个月的OS，并较单纯TAC…
95P Additional survival follow-up of TACTICS-L ... - Annals of …
TACTICS-L is a prospective study to evaluate safety and efficacy of combination of TACE and LEN in HCC patients who are not eligible for curative therapy (uHCC). The primary analysis was conducted at cutoff date of April 2021 (minimum follow-up 12 months), and median progression-free survival (PFS), the primary endpoint, was 24.4 months.
Transcatheter arterial chemoembolization therapy in combination ...
2022年1月19日 · Combination therapy with TACE and molecular targeted agents has been reported to have higher antitumor efficacy than respective monotherapies. This study aims to evaluate safety and efficacy of combination of TACE and lenvatinib in uHCC patients. Methods: Phase II, prospective, multicenter, single-arm study was conducted in 19 Japanese sites.
The present phase 2, prospective, multicenter, single-arm trial, the TACTICS-L trial, investigated the effi-cacy and safety of TACE plus lenvatinib (LEN), a drug that more strongly promotes vascular normalization and has a better objective response rate (ORR) than sorafenib (jRCTs031180074).
難治性の肝細胞がんに対して世界初の画期的な根治治療法を開発 肝細胞がんの標準治療確立へ道筋 | NEWS RELEASE …
2019年7月31日 · そして、分子標的薬レンバチニブをこのステージの肝がんの患者さんに投与し、その後TACEを加えるというLEN-TACE sequential治療によりTACE単独で治療を行うより、約2倍近く全生存期間を延長させることを証明しました。
TACTICS-L is a prospective study to evaluate safety and efficacy of combination of TACE and LEN in HCC patients who are not eligible for curative therapy (uHCC). The primary analysis was conducted at cutoff date of April 2021 (minimum follow-up 12 months), and median progression-free survival (PFS), the primary endpoint, was 24.4 months.
Lenvatinib Combined With Transarterial Chemoembolization as
2023年1月1日 · Purpose: Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patients with advanced HCC.
Efficacy and Safety of Lenvatinib-Transcatheter Arterial ...
Introduction: We evaluated the efficacy and safety of lenvatinib-transcatheter arterial chemoembolization (LEN-TACE) sequential therapy for patients (n = 88) with intermediate-stage hepatocellular carcinoma (HCC).
fastsmt/fastsmt/language/objects.py at master · eth-sri/fastsmt
""" Pop tactic from the beginning of strategy and return tuple consisting of single tactic and remaining strategy. tactics = get_tactics(str(strategy)) if len(tactics) == 1: